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Modification of the Carcinogenic Process
in Colorectal Cancer by Endogenous and
Exogenous Factors: Effect of Colestipol
Hydrochloride on Tumors Induced by
Dimethylhydrazine
by J. Patrick Daugherty*
The effect of the bile acid sequestrant, colestipol hydrochloride, on the incidence of dimethylhy-
drazine-induced tumors of the large intestine was determined in male Swiss mice. The subcutaneous
administration of dimethylhydrazine (15 mg/kg) produced tumors in approximately 89% of the ani-
mals with an average of 1.70 tumors per tumor-bearing animal. When carcinogen-treated animals
received dietary colestipol (0.52%, w/w) from 4 weeks prior to the first injection of dimethylhydra-
zine until the time of death, there was an increase in the number of tumors per tumor-bearing ani-
mal to 2.23. In an attempt to understand the nature of this enhancement, animals were adminis-
tered dietary colestipol at different times in relation to the administration of the carcinogen. The
number of tumors per tumor-bearing animal for the different protocols was: post-initiation colesti-
pol exposure, 1.70; colestipol exposure concomitant with dimethylhydrazine, 1.41; pre-initiation col-
estipol exposure, 2.23.
Thus, colestipol appeared to function both as an anticarcinogen and as a promoter (pre-initiation).
Since colestipol has the capacity to bind a number of chemical agents, the different biological ef-
fects probably reflect the multifactorial nature of colorectal cancer with the end result dependent
on the balance between opposing factors. The selective administration of colestipol in relation to
carcinogen administration may prove useful in elucidating the various factors involved in the
etiology of this disease.
Introduction
Cancer of the colon and rectum is the most com-
mon visceral neoplasm in the United States. Silver-
berg (1) has estimated that approximately 120,000
new cases of colorectal cancer will be diagnosed and
about 50,000 people will die of this neoplasm this
year.
The etiology of human colorectal cancer is not
well understood. Although certain conditions and
genetic factors are known to predispose to colorec-
tal cancer, the greatest emphasis in the pathogen-
esis of this disease has been placed on environmen-
tal factors. The importance of dietary factors has
been emphasized from epidemiological observations
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(geographic correlations, migrant studies, low-risk
populations, dietary modification trials), and inten-
sive clinical and experimental studies have investi-
gated the role of such factors in the etiology of colo-
rectal cancer. The high incidence of cancer of the
colon and rectum in Western countries has been
speculatively related to the consumption of inade-
quate quantities of fiber by Burkitt (2), to the con-
sumption of excess of fat and beef protein by Wyn-
der (3), and to low amounts of vegetable consump-
tion by Correa (4). These food items are not believed
to be carcinogenic from the standpoint of initiation,
but are viewed as promoting agents in which they,
in some way, provide a more favorable environment
for initiating carcinogens.
The reported carcinogenic nature of dimethylhy-
drazine (DMH) by Druckrey et al. (5) has led to nu-
merous studies in investigating the carcinogenic
process of colorectal cancer. Although epidemiologi-J. P. DA UGHERTY
cal observations do not establish a causative rela-
tionship between dietary factors and cancer, numer-
ous experimental animal studies, as reviewed by
Reddy et al. (6) have shown that high fat and pro-
tein diets tend to promote DMH-induced colon carci-
nogenesis.
The experimental protocol usually involves
weekly injections of DMH for 5-6 months or longer,
and tumors are frequently induced at sites other
than the large intestine. A treatment period of 10
weeks was reported by Clapp et al. (7) to produce
primarily tumors of the large intestine with few
transitional lesions. This schedule was attractive
from the standpoint of studies on the modification
of carcinogenesis since either an increase or a
decrease in tumor incidence could be observed.
Colestipol hydrochloride (Colestid; COL) is a high
molecular weight anion exchange resin. It is a co-
polymer of diethylenetriamine and 1-chloro-2,3-epox-
ypropane, with approximately one out of five amine
nitrogens protonated (chloride form). Colestipol was
shown by Stanley et al. (8) to increase the fecal ex-
cretion of cholate about 5-fold in healthy volunteers,
and similar findings were reported by Rubulis et al.
(9) and Grundy and Mok (10). The ability of COL to
bind bile acids in vitro was demonstrated by Krit-
chevsky and Story (11, 12). The complex between
COL and bile acids is excreted in the feces, thereby
resulting in partial removal of bile acids from the
enterohepatic circulation. Colestipol is used clini-
cally as adjunctive therapy to treat patients with
primary hypercholesterolemia (elevated low density
lipoprotein). In a review of the clinical use of COL,
Heel et al. (13) reported that the increased fecal loss
of bile acids leads to an increased oxidation of cho-
lesterol to bile acids, a decreased level of low den-
sity lipoproteins in the serum and a decreased level
of serum cholesterol.
The pharmacological properties of COL appear
similar to those of another bile acid sequestrant,
cholestyramine (Questran; CTY). The addition of di-
etary CTY (2%, w/w) was reported by Nigro et al.
(14) and Asano et al. (15) to increase the incidence of
intestinal tumors induced by DMH and related
agents in rats. In another study by Nigro et al. (16),
CTY and candicidin (another serum cholesterol-low-
ering agent) increased the incidence of intestinal tu-
mors induced by azoxymethane. However, the dis-
tribution of the increased number of tumors was dif-
ferent for the two agents. Aluminium hydroxide
(Aludrox), a widely used antacid with incidental bile
acid-binding properties, was initially reported by
Cruse et al. (17) to increase intestinal cancer induced
by DMH in rats. However, a subsequent study by
Cruse et al. (18) failed to demonstrate any enhance-
ment ofDMH-induced intestinal tumors.
It is of interest that MacGregor (19) reported the
case of a male who died of cancer of the small intes-
tine following an 8-year history of CTY use, and
Sachatello (20) reported a case of colon cancer in a
29-year old male following a 5-year history of CTY
therapy secondary to resection of the terminal il-
eum for trauma.
Therefore, based on the experimental data and
the clinical case reports, a study was undertaken to
examine the effect of COL on DMH-induced tumors
of the large intestine in mice.
Materials and Methods
Male Swiss mice (ICR/SAF), obtained from our
own breeding colony and housed in a clean, con-
ventional room with restricted human access, were
provided food (pelleted laboratory chow; Ralston
Purina Co., St. Louis, Missouri) and water ad libi-
tum. The animals were assigned to one of four
treatment groups at 10 weeks of age. The animals
were housed five per cage in plastic cages with
hardwood bedding (Betta chip) in an air-conditioned
room with 12-hr intervals of light and darkness.
Fifty-five animals were assigned to each treatment
group.
Mice in groups I (control) and II (DMH alone)
were maintained on unmodified laboratory chow for
life. Mice in group I received weekly injections of
0.9% NaCl (pH 6.5 with sodium bicarbonate and
containing 0.001 M EDTA) at the same time that
mice in group II received weekly subcutaneous in-
terscapular injections of DMH (15 mg/kg body
weight); all injections were started when the mice
were 14 weeks of age. The DMH (Aldrich Chemical
Co., Milwaukee, WI) solution was prepared daily in
0.9% NaCl as described above. Animals in groups
III (COL) and IV (DMH plus COL) received a diet
containing 0.52% COL for various periods of time.
The COL-containing diet was prepared by Ralston
Purina Co., and the COL was a gift of Upjohn Co.
The administration of DMH to animals in group IV
was as described above for animals in group II. Sur-
viving animals were killed by cervical dislocation at
40 weeks of age, 26 weeks after the first DMH injec-
tion.
The dose schedule was chosen to provide a quan-
tity of tumors such that either an increase or a de-
crease in the incidence could be observed. The dose
of COL approximates, on a per weight basis, the
amount administered to patients, but is about 25%
ofthe level of CTY used in previous studies.
Mice were killed by cervical dislocation and ex-
amined grossly. The gastrointestinal tract was in-
flated with Tellyesniczky's fixative in situ, removed
from the animal, the intestines cleared with methyl
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salicylate, stained with Wright's stain, and exam-
ined for tumors with the aid of a dissecting micro-
scope at 3 x magnification. The intestines were
cleared according to the techniques of Spalteholz (as
described by Emmel and Cowdry, (21) and Larsen
and Ainsworth (22) as modified by Clapp et al. (7).
The clearing procedure allows the tumor nodules to
be recognized and differentiated from Peyer's
patches. The location of the tumors was noted on a
schematic drawing for subsequent identification.
Results
The data in this report involved primary tumors
in the large intestine induced by repeated injections
of DMH. None of the animals which did not receive
DMH, either those on unmodified or those on COL-
containing diet, developed tumors anywhere along
the gastrointestinal tract. Furthermore, no tumors
were observed in the small intestine of those ani-
mals treated with DMH. Microscopic examination of
the tumors revealed the full spectrum of neoplastic
lesions as described by Thurnherr et al. (23) and
Deschner (24).
The average body weight of all mice at the begin-
ning of the treatments was 32 g. Thereafter the ani-
mals were weighed weekly and the average weight
of the members of each group did not differ signifi-
cantly. There was a slow, progressive weight gain
up to 20 weeks after the first DMH injections,
reaching an average of 46 g, with a decrease in
weight during the last month to an average of 43 g
in the DMH-treated animals. The majority of the
animals remained in good condition until the last
few weeks prior to autopsy. The animals, as a rule,
did not develop diarrhea.
In the first experiment the animals were placed
on the COL diet at ten weeks of age and remained
on such throughout their remaining life. Of the 49
DMH-treated mice on the unmodified diet that sur-
vived to autopsy, 88% developed tumors of the
large intestine; and 85% of the 46 DMH plus COL
animals that survived to autopsy developed tumors
(Table 1). However, while the DMH group devel-
oped 1.70 tumors per tumor-bearing animal, the
DMH plus COL group developed 2.23. Tumors were
induced along the length of the large intestine. The
tumors in both treatment groups tended to occur
most frequently in the distal large intestine (Fig. 1).
The majority, or 64%, of the isolated tumors in the
DMH group were located in the three cm segment
of the large intestine above the anus, while the
proximal 3 cm of the colon contained relatively few
tumors (18%); the corresponding percentages for
the DMH plus the COL group were 69% and 8%,
respectively. The DMG group developed 36 tumors
in the distal 2 cm of the large intestine, whereas the
DMH plus COL group developed 50 tumors.
In the post-initiation experiment, the COL diet
was initiated at the termination of the DMH injec-
tions. The survival of the animals and the percen-
tage of surviving animals with tumors was essen-
tially the same as when the animals received life-
time COL. However, the number of tumors per tu-
mor-bearing animal was not significantly different
among the two groups (Table 2). The animals re-
ceiving DMH contained 1.55 tumors per tumor-
bearing animal, while the group receiving DMH
plus COL contained 1.71. The distribution of the tu-
mors was similar to the previous experiment with
61% of the tumors in both groups occurring within
the distal 3 cm of the large intestine (Fig. 2). The
DMH group contained 29 tumors in the distal 2 cm
of the large intestine, while the DMH plus COL
group contained 34.
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FIGURE 1. Distribution of tumors in the large intestine
following dimethylhydrazine and lifetime colestipol.
Table 1. Tumors of the large intestine in mice after dimethylhydrazine administration with or without colestipol.a
Number of mice Number of tumors
Treatment group Surviving With Tumors Total Per tumor-bearing animal
Control 55 0 0 0
DMH 49 43 73 1.70
COL 55 0 0 0
DMH+ COL 46 39 87 2.23
aAnimals received ten weekly injections (between 14 and 24 weeks of age) of dimethylhydrazine (15 mg/kg). Animals were fed
the colestipol diet from 10 weeks of age until death.
DMH DMH+COL
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In another experiment, the animals received die-
tary COL concomitantly with DMH injections. The
fraction of surviving mice with tumors was 84% in
the DMH group and 71% in the DMH plus COL
group (Table 3). Furthermore, the addition of die-
tary COL decreased the number of tumors per tu-
mor-bearing animal from 1.79 to 1.41. The relative
distribution of tumors in the large intestine was
similar to the previous studies (Fig. 3). However,
the DMH group developed 40 tumors in the distal 2
cm of the large intestine, and the DMH plus COL
group developed only 23.
In the last experiment the COL diet was adminis-
tered for four weeks prior to the DMH injections.
The formation of tumors was increased from 1.64 to
2.23 tumors per tumor-bearing animal (Table 4). The
relative distribution of tumors (Fig. 4) did not
change significantly. However, the number of tu-
mors in the distal 2 cm of the large intestine in-
creased from 41 in the DMH group to 66 in the
DMH plus COL group.
Discussion
In the experiments reported in this paper, tu-
mors of the large intestine were never observed in
non-DMH-treated animals. The noncarcinogenic na-
ture of COL observed in mice under the conditions
used in these experiments confirmed a previous re-
port by Webster and Bollert (25) on the lack of carci-
nogenicity of COL in rats and dogs.
When the results of the four separate experi-
ments were combined, the schedule of DMH injec-
tions used in these studies produced tumors in
88.8 + 4.0% (range: 84-94%) of the animals within
26 weeks from the initial DMH injection, and re-
sulted in 1.67 ± 0.10 tumors per tumor-bearing ani-
mal (range: 1.55-1.79). The tumors arose primarily
Table 2. Tumors of the large intestine of mice after dimethylhydrazine administration followed by colestipol.a
Number of mice Number of tumors
Treatment group Surviving With Tumors Total Per tumor-bearing animal
Control 55 0 0 0
DMH 45 40 62 1.55
COL 55 0 0 0
DMH + COL 46 42 72 1.71
aAnimals received ten weekly injections (between 14 and 24 weeks of age) of dimethylhydrazine (15 mg/kg). Animals were fed
the colestipol diet from 24 weeks of age until death.
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FIGURE 2. Distribution of tumors in the large intestine
following dimethylhydrazine and post-initiation colestipol.
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FIGURE 3. Distribution of tumors in the large intestine
following dimetbylhydrazine with concomitant colestipol.
Table 3. Tumors of the large intestine in mice after dimethylbydrauine administration with concomitant colestipol.a
Number of mice Number of tumors
Treatment group Surviving With Tumors Total Per tumor-bearing animal
Control 55 0 0 0
DMH 50 42 75 1.79
COL 55 0 0 0
DMH+ COL 52 37 52 1.41
aAnimals received ten weekly injections (between 14 and 24 weeks of age) of dimethylhydrazine (15 mg/kg). Animals were fed
the colestipol diet during the time they received the injections of dimethylhydrazine.
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in the distal portion of the large intestine and were
usually isolated.
The initial experiment was conducted with ani-
mals which received dietary COL during the last
75% of their life. Since a significant increase in the
incidence of DMH-induced tumors was found, addi-
tional experiments were designed to determine at
what stage in the carcinogenic process COL was
producing its effects. The results indicated that
COL was not behaving as a promotoer in the classi-
cal sense of post-initiation promotion. Rather, COL
was found to be a pre-initiation promoter. Further-
more, when COL was administered concomitantly
with the carcinogen, it behaved as an anticarcino-
gen.
The mechanism by which COL influenced DMH-
induced tumorigenesis is unknown. It is apparent
that any attempts to develop a mechanism of action
must approach the problem from the point of view
of a multistage/multifactorial process of DMH-in-
duced carcinogenesis. Numerous studies, as re-
viewed by Maskens (26), indicate that DMH is meta-
bolically activated to an electrophilic compound ca-
pable of alkylating macromolecules in colon epithe-
lial cells. Thus, each injection of DMH is capable of
producing permanent and transmissible changes in
some cells that will eventually lead to cancer. How-
ever, numerous factors may play a role in modifying
the carcinogenic process. These modifying agents
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FIGuRE 4. Distribution of tumors of the large intestine
following dimethylhydrazine and pre-initiation colestipol.
may have an additive, synergistic, or inhibitory ef-
fect on the activity of a given carcinogen. The ob-
served biological effects of COL on DMH-induced
carcinogenesis are probably related to the influence
of COL on more than one factor, and some insight
into future studies can be ascertained by reviewing
some of the factors known to promote or inhibit
DMH-induced cancer of the large intestine.
Since COL is a bile acid-sequestering agent, it is
important to examine the relationship of bile acids
to cancer of the large intestine. Cholesterol is the
major, and probably sole precursor of bile acids.
During normal digestion bile acids are secreted into
the intestines via the bile from the liver and gall-
bladder. Bile acids emulsify the fat and lipid mate-
rials in food, thus facilitating absorption. A major
portion of the bile acids that are secreted are reab-
sorbed from the intestines and returned via the por-
tal circulation to the liver, thus completing the en-
terohepatic cycle. The decrease in serum cholesterol
levels as a result of COL therapy is due to seques-
tering bile acids which result in an increased fecal
excretion of bile acids and interference with their
normal enterohepatic circulation. As a result there
is a compensatory increase in cholesterol catabolism
to form additional bile acids along with an increased
synthesis of cholesterol in the liver.
Evidence for the importance of bile acids as can-
cer promoters in the large intestine has developed
from studies by Chomchai et al. (27), Narisawa et al.
(28), Reddy et. al. (29-31), and others. The mechan-
ism of action of tumor promotion by bile acids is un-
known. However, it is of interest that Kulkarni et
al. (32) reported that lithocholic acid produced
single-strand breaks in the DNA of L1210 leukemia
cells, and Kulkarni and Yielding (33) reported single-
strand breaks in DNA from crypt cells of mouse co-
lon induced by lithocholic acid.
Thus, the anticarcinogenic effect of COL, ob-
served when COL was administered simultaneously
with DMH, can be rationalized on the basis of COL
binding the bile acids in the intestinal lumen and
preventing the interaction of these tumor promo-
ters with colonic mucosa. However, when animals
were given dietary COL before, during and after
DMH, or merely before the carcinogen, there was
Table 4. Tumors of the large intestine in mice after dimethylhydrazine administration following colestipol.a
Number of mice Number of tumors
Treatment group Surviving With Tumors Total Per tumor-bearing animal
Control 55 0 0 0
DMH 48 45 74 1.64
COL 55 0 0 0
DMH + COL 46 44 98 2.23
aAnimals received ten weekly injections (between 14 and 24 weeks of age) of dimethylhydrazine (15 mg/kg). Animals were fed
the colestipol diet for 4 weeks prior to the injections of dimethylhydrazine.
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an increased incidence of tumors in the large intes-
tine. The observed duality of effects due to COL is
similar to those reported for butylated hydroxy-
toluene (BHT). When BHT was given prior to and
concurrently with 2-acetylaminofluorene, as re-
ported by Ulland et al. (34), or azoxymethane, as re-
ported by Weisburger et al. (35) it protected against
carcinogenesis. However, Peraino et al. (36) and
Weisburger et al. (35) demonstrated a promoter ac-
tivity for BHT when given after 2-acetylaminofluo-
rene or azoxymethane, respectively.
Conflicting results are frequently reported when
investigating the effects of bile acid binding agents
on carcinogenesis of the large intestine. Nigro et al.
(14, 16) and Asano et al. (15) reported that the coad-
ministration of CTY at a level of2% (wlw) increased
the incidence of tumors. Aluminum hydroxide was
initially reported by Cruse et al. (17) to enhance
DMH-induced carcinogenesis, but no promoter ac-
tivity was found in a latter study by Cruse et al.
(18).
The effect of bran, which binds bile acids to a
lesser degree than CTY or COL, has been widely
studied since the epidemiological studies by Burkitt
(2) implicated low-fiber diets as a factor in the etiol-
ogy of human colorectal cancer. However, the find-
ings of Draser and Irving (37), Hill (38, 39), and East-
wood et al. (40) have challenged these findings. It
has been argued that dietary fiber would be anticar-
cinogenic in that it would increase fecal output and
decrease intestinal transit time. Barbolt and Abra-
ham (41) reported bran decreased carcinogen-in-
duced cancer, Cruse et al. (42) reported that bran
had no effect on the incidence of cancer, and Clapp
et al. (43) presented results that showed bran to be
a tumor promoter. The discrepancies in the results
of experimental systems could be due to differences
in the fiber components, differences in nonfiber
components, absorption of other factors by the fi-
ber, and different effects on the intestinal flora. The
variability of dietary fiber in animal diets and the
relevance of this variability to experimental studies
has recently been discussed by Wise and Gilburt
(44).
The observed promoter activity of bile acid-bind-
ing agents is usually explained on the basis that the
binding to bile acids results in an increased delivery
of these tumor promoters to the large intestine.
However, these bile acids are sequestered in the
resin matrix, and this explanation may be insuffi-
cient to account for the promoter activity. Indeed, it
is difficult to explain both the anticarcinogenic and
promoter activity of COL based on its interactions
with bile acids. Much work is obviously required to
unravel the complex interrelationships between bile
acids, bile acid-sequestering agents and cancer of
the large intestine. The nonselective nature of bind-
ing as well as variability in composition and purity
of bile acid binding agents serves to further empha-
size the need for additional experimental work in
this area.
It is well known that COL and CTY are nonspe-
cific anion-exchange resins; their binding capability
is not restricted to bile acids, but includes other
acidic drugs and biomolecules. The chronic use of
COL was reported by Miller et al. (45) to be associ-
ated with an increased bleeding tendency due to hy-
poprothrombinemia from vitamin K deficiency, and
Ko and Royer (46) reported that warfarin and tetra-
cycline were significantly bound by COL. A large
portion of vitamin B12-intrinsic factor complex, folic
acid, and iron citrate was reported by Leonard et al.
(47) to be bound by COL and CTY.
In view of the binding of vitamin B12-intrinsic fac-
tor complex by CTY and COL, it is of interest that
Yamamoto (48) reported that vitamin B12 was neces-
sary for the formation of DMH-induced tumors.
Studies by Cook and McNamara (49) have suggested
the involvement of vitamin E in colorectal cancer.
Vahouny et al. (50) demonstrated that commercial
ion-exchange resins and certain dietary fibers se-
quester phospholipids from micellar media. The ef-
fect of these agents on intestinal morphology and
carcinogen-induced tumors is unknown. Vahouny et
al. (51) presented evidence that bile acid seques-
tering agents induce morphological changes in the
intestines, and previous studies by Cassidy (52, 53)
had reported similar findings. It was suggested that
the alterations induced in intestinal morphology
may provide a means of increasing the sensitivity of
the colon to chemical carcinogens.
The promoting activity of nonspecific injury was
demonstrated by Rous and Kidd (54), and the tumor-
promoting effect of tissue injury on DMH-induced
carcinogenesis was described by Pozharisski (55). A
clustering of experimental tumors around suture
lines or colostomy stomas has been reported by
Witting (56) and Harte et al. (57) and others, and hu-
man colon cancers have been reported by Floyd et
al. (58) to occur with increased frequency at colonic
suture lines. Mueller and Thornbury (59) described
colon cancer as a complication of ureterosigmoidos-
tomy.
Major small bowel resection was shown by Wil-
liamson et al. (60, 61) to result in long-term adaptive
mucosal hyperplasia in the remaining bowel. When
a single initiating dose of DMH was injected into
rats, followed by resection of the distal third of the
small intestine, Tilson (62) reported an increase in
the number of tumors. Celik et al. (63) observed an
increased incidence of tumors in the dilated splenic
flexure following jejunocolic transposition and sug-
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gested that the observed chronic irritation and in-
flammation may play a role in this effect.
It is tempting to speculate that the pre-initiation
promotion observed with COL in the studies re-
ported in this paper may be due to the increased
sensitivity of the colonic mucosal cells to DMH fol-
lowing four weeks of exposure to COL.
Another possible factor which may be influenced
by COL is the immune system. There is increasing
evidence that endogenous and exogenous lipids are
involved in some way in modulating or regulating
the immune system. The recent reports, as re-
viewed by Broitman (64), on the association of
lowered cholesterol levels with increased cancer of
the large intestine, is of interest. The available evi-
dence, as reviewed by Posner et al. (65) suggests
that dietary manipulation which results in tumor
promotion also results in immunosuppression.
In addition, low density lipoprotein was reported
by Morse et al. (66) to inhibit lymphocyte prolifera-
tion. The binding of low density lipoprotein by hu-
man fibroblasts and lymphocytes modulates the
rate of uptake, esterification, and synthesis of cho-
lesterol as reported by Curtis and Edington (67) and
Ho et al. (68). Vitale and Broitman (69) suggested
that the changes in the concentration oflipoproteins
may enhance the growth of premalignant cells.
Since COL alters the concentration of low density
lipoprotein it is possible that the promotion effects
of this agent are related to the lipoproteins.
Monocytes and macrophages are involved in reg-
ulating the immune response. These cells may func-
tion as suppressor cells, exerting their suppressor
effect on other lymphoid cells by secreting prosta-
glandins. Balch and Tilden (70) reported that prosta-
glandin-producing suppressor cells were involved in
the decreased lymphocyte function observed in
some cancer patients, and the decreased response
to mitogens could be restored by incubation with in-
domethacin.
Jaffe (71) Bennett and Del Tacca (72) Cumming
and Robertson (73) and Bennett et al. (74) have de-
scribed the production of prostaglandins by various
human and animal tumors. The growth of trans-
plantable tumors was reported by Sykes and Mad-
dox (75) Levine et al. (76) and Lynch and Salomon
(77) to be inhibited by prostaglandin inhibitors. Pol-
lard and Luckert (78) observed that indomethacin
reduced the incidence and frequency of DMH-in-
duced tumors in the rat colon. The effect of COL on
prostaglandins in unknown.
Although the precise mechanism for either the
anticarcinogenic or promoter effect of COL remains
to be elucidated, the effects are probably indirect
since COL is not absorbed from the gastrointestinal
tract. The multifactorial nature of carcinogenesis
suggests that the effects of COL are related to: (a)
the bile acid sequestering activity of this agent; (b)
alterations in absorptive or morphological proper-
ties of tissues in such a way that the carcinogenicity
of DMH is enhanced; (c) the binding to other biomol-
ecules which may be involved in malignant transfor-
mation either as agents of promotion or inhibition;
(d) modification of immunological processes; and/or
(e) alterations in the intestinal flora. It is apparent
that COL alters opposing aspects of the carcino-
genic process, that is, protective and predisposing.
The end result depends on the balance between op-
posing factors. Current studies are underway to ex-
amine the role of these factors in the modification of
DMH-induced cancer by COL.
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